Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21376352 | 0.88 | ROCK2 (0.70) | ROCK2ROCK1 | |
| SCHEMBL20181388 | 0.88 | ROCK2 (0.70) | ROCK2ROCK1 | |
| SCHEMBL18254788 | 0.80 | ROCK2 (0.77) | ROCK2ROCK1 | |
| SCHEMBL20181637 | 0.78 | ROCK1 (0.69) | ROCK2ROCK1 | |
| SCHEMBL21376141 | 0.78 | ROCK1 (0.69) | ROCK2ROCK1 | |
| SCHEMBL20168523 | 0.75 | ROCK1 (0.61) | ROCK2ROCK1 | |
| SCHEMBL20181639 | 0.74 | ROCK2 (0.74) | ROCK2ROCK1 | |
| SCHEMBL18254797 | 0.74 | ROCK1 (0.68) | ROCK2ROCK1 | |
| SCHEMBL20168369 | 0.73 | ROCK2 (0.56) | ROCK2ROCK1 | |
| SCHEMBL18254786 | 0.71 | ROCK2 (1.00) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807966-B2 | Heterocyclic compounds as kinase inhibitors | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190284157-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2019-09-19 | — | — | US | disclosed |
| WO-2018094362-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807966-B2 | Heterocyclic compounds as kinase inhibitors | MAP3K1, MAP3K20, MAP3K5 | ROCK2 76/4885ROCK1 67/4885 |
| US-20190284157-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K5 | ROCK2 76/4885ROCK1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.